TP53 and colorectal carcinoma: To study the immunoexpression of the TS, p53, COX2, EGFR, MSH6 and MLH1 biomarkers in patients with colorectal carcinoma; and to make correlations with the degree of cell differentiation, tumor staging and clinical-pathological prognostic factors.